Conference icon

Conference

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

Publication status:
Published

Actions


Authors


Genovese, MC More by this author
Keystone, E More by this author
Drescher, E More by this author
Berclaz, P-Y More by this author
Expand authors...
Volume:
64
Issue:
10
Pages:
S1049-S1050
Publication date:
2012-10-05
ISSN:
0004-3591
URN:
uuid:43610c22-550d-430a-b111-678baf5561ff
Source identifiers:
366494
Local pid:
pubs:366494

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP